What Метеоспазмил Treats: Main Uses and Benefits

The primary therapeutic domain of this medication is the symptomatic management of functional gastrointestinal disorders characterized by discomfort. It is applied in addressing specific symptom clusters.

---

Symptomatic Support for Functional Spasm and Pain

This medication is commonly used to help manage symptoms related to physical discomfort and heightened physiological activity, such as sudden and often intense abdominal discomfort and cramping. It provides supportive relief that helps ease the overall symptom burden caused by these painful spasms. It is relevant in conditions involving episodic or fluctuating manifestations.

“It provides support that helps ease the overall symptom burden.”

Management of Digestive Gas, Bloating, and Swelling

The product is applied in scenarios where additional symptomatic support is needed to help address symptoms that create noticeable physiological strain related to excess gas accumulation, bloating, and abdominal distension. This is often used during phases when symptoms become more noticeable, assisting with maintaining functional stability.

The medication is generally used for managing symptoms associated with functional bowel disorders, abdominal discomfort, and excess intestinal gas.

---

Quick Fact: Assistance for Noticeable Physiological Strain

---

Who Can and Cannot Use Метеоспазмил?

The population eligibility for Метеоспазмил (Alverine citrate, Simeticone) is defined strictly by official regulatory documents, primarily restricting use based on age, hypersensitivity, and physiological state.

---

Contraindicated and Excluded Populations

Category	Regulatory Status	Restriction Basis
Pediatric Population	Contraindicated	Safety and efficacy are not established; labeled for adult use only (under 18 years).
Hypersensitivity	Contraindicated	Known allergy to Alverine citrate, Simeticone, or any excipients.
Bowel Conditions	Contraindicated	Patients with paralytic ileus or intestinal obstruction must not use the medication.

---

Conditional Use and Avoidance

• Pregnancy and Lactation: Use should be avoided during both pregnancy and breastfeeding as a precautionary measure due to insufficient clinical data to exclude risk.

• Hepatic Function: Continued eligibility is conditional. Treatment must be discontinued immediately if patients experience signs of liver injury, such as jaundice or if hepatic aminotransferases are elevated above the labeled threshold.

• Allowed Use: The medication is established for use in the adult population (18 years and older) who do not have any listed absolute contraindications.

Interactions with Other Medicines and Products

The regulatory profile for Метеоспазмил (Alverine citrate/Simeticone) is characterized by a general absence of documented clinically significant interactions with the majority of co-administered medicines.

---

Documented Interaction Patterns

The most important documented interaction relates to one of the active components, Simeticone, and its potential to interfere with the absorption of certain co-administered substances. This interaction is officially described as follows:

Classification	Interacting Substance	Official Constraint or Outcome
Exposure-Modifying	Levothyroxine (Thyroid Hormone)	Simeticone may reduce the absorption of Levothyroxine, potentially resulting in diminished hormone exposure in the body.
Timing-Based Rule	Levothyroxine	Administration timing is constrained: Levothyroxine must be administered at least 4 hours before or after drugs known to interfere with its absorption.

---

Other Interaction Contexts

Official regulatory documents generally classify the risk of drug-drug interactions for the combination product as not clinically significant. There are no formal interaction-based restrictions documented for use with alcohol, food, or herbal products in the primary regulatory labeling. Furthermore, no specific population-dependent factors (e.g., hepatic or renal function) are explicitly stated to alter the severity of the drug’s overall interaction profile.

The action of Метеоспазмил is based on the coordinated, dual mechanism of its two active components, involving the modulation of gastrointestinal motor function and intraluminal gas dynamics.

Modulation of Gut Wall Spasticity and Visceral Sensation

This core pharmacological domain is executed by Alverine citrate, which acts on two distinct biological processes within the gastrointestinal tract. Primarily, it exerts a musculotropic antispasmodic effect by modulating calcium ion influx in the smooth muscle cells of the gut wall, resulting in a decrease in the tonicity of excessive contractions. Secondly, Alverine engages with 5-HT1A receptors, a component of the peripheral nervous system, which modulates exaggerated afferent signaling, influencing visceral perception pathways. This coordinated modulation adjusts physiological motor and sensory activity in the gut.

Physical Regulation of Intraluminal Gas Dynamics

This domain is defined by the purely physical action of Simeticone within the intestinal lumen. As a chemically inert antifoaming agent, Simeticone reduces the surface tension of trapped gas bubbles. This action initiates a coalescence cascade, causing numerous small, fixed gas pockets to merge into larger, more mobile bubbles. The resulting physiological change is the normalization of intraluminal gas distribution, which promotes the movement of gas pockets toward the extremities of the digestive tract, thereby reducing the mechanical stress exerted by intraluminal gas on the gut wall.

The administration of the fixed-dose combination product containing Alverine citrate (60 mg) and Simeticone (300 mg) follows standardized instructions. The product is for oral use and is supplied as a soft capsule.

The standard posology for adults dictates a typical dose of one capsule per instance. The frequency for this adult regimen is set at two to three times daily, which defines the maximum allowable daily intake at three capsules. This regimen is defined by contextual timing rather than a rigid clock schedule; administration is directed to occur at the beginning of meals or on an as-needed basis when pain is experienced. This flexibility aligns the use with the episodic nature of the symptoms the medicine is intended to address.

A key procedural constraint is that the capsule must be swallowed whole using water; it is not formulated to be opened or chewed prior to ingestion. Furthermore, the medicine is FOR ADULTS ONLY; the required dosage, safety profile, and administration guidelines have not been established for use in the pediatric patient population. This limits the application of the regimen to individuals aged 18 and older. The administration protocol is therefore defined by constraints on dosing frequency, procedural intake, and age-group eligibility.

Research evidence / Overview of studies for Метеоспазмил

Evidence for Use in Functional Bowel Disorders (IBS)

The primary research for the Alverine/Simeticone combination was evaluated in studies exploring outcomes related to conditions characterized by fluctuating or episodic manifestations such as Irritable Bowel Syndrome (IBS). The research base includes Randomized Controlled Trials (RCTs), which are a key standard of evidence in clinical research, along with Systematic Reviews and Meta-Analyses. These studies primarily enrolled adults who experienced moderate to severe symptoms consistent with Irritable Bowel Syndrome.

Studies explored a variety of patient-reported outcomes describing perceived discomfort. Key endpoints examined in the research included the intensity of abdominal pain and bloating, as well as assessments of changes in overall quality of life related to IBS. Findings described patterns observed in the studies over defined time intervals, often focusing on short-term changes (around four weeks) in acute symptoms. The evidence base for this indication is largely derived from RCTs, but long-term effects are not fully established.

---

Evidence for Procedural Support (Colonoscopy)

Research has also examined the combination drug in a very specific, acute clinical scenario: when added to standard practice during bowel preparation for a colonoscopy. These studies involved randomized and comparative trials where researchers monitored physiological strain related to the presence of gas.

In this context, the studies focused on endpoints directly related to the procedure itself, primarily measuring the visual quality of bowel preparation and the measured presence of colonic bubbles or foam. Studies monitored the presence of such bubbles and reported patterns of lower measurement when the combination was used alongside standard preparatory agents. The research evidence for this specific application is categorized as Moderate. This research stream does not provide information regarding the daily management of chronic functional intestinal symptoms, as its focus is on acute, procedural use.

---

Key Research Gaps and Uncertainties

Data on long-term outcomes for continuous use is limited, and there is a research gap concerning the experience of specific age or disease sub-groups. For instance, there is limited information available regarding the use and observed changes in children, adolescents, or older adult populations. Additionally, comparative evidence for a direct comparison against a non-active control in all studied contexts is lacking. Findings describe group patterns, and research findings do not predict whether an individual will respond similarly.

Key Studies & References

1. AVARIN (Simethicone 300 mg & Alverine Citrate 60 mg) Summary of Product Characteristics (SmPC) - Rwanda FDA

Common questions about Метеоспазмил (FAQ)

Q: What is Метеоспазмил?

A: Метеоспазмил is a medication that contains two active ingredients: Alverine citrate and Simethicone. It is used to relieve symptoms associated with functional bowel disorders, particularly those involving abdominal discomfort, pain, flatulence, and bloating.

Q: How does Метеоспазмил work?

A: The two ingredients work in combination:

• Alverine citrate is an antispasmodic agent. It helps to relax the smooth muscles in the gut wall, which reduces painful spasms and contractions in the digestive tract.
• Simethicone is an anti-foaming agent. It works by reducing the surface tension of gas bubbles in the stomach and intestines, causing them to break up. This facilitates the passage or absorption of gas, helping to relieve bloating and flatulence.

Q: What conditions is Метеоспазмил used to treat?

A: Метеоспазмил is primarily used to relieve symptoms of Irritable Bowel Syndrome (IBS) and other functional digestive disorders. These symptoms typically include:

• Abdominal pain or discomfort
• Cramping
• Excessive gas (flatulence)
• Bloating

Q: What are the possible common side effects of Метеоспазмил?

A: Like all medicines, Метеоспазмил can cause side effects, although not everybody gets them. Common, but typically rare, side effects may include:

• Nausea
• Constipation
• Headache
• Allergic reactions (e.g., hives or skin rash)

If you experience a severe allergic reaction (such as swelling of the face, tongue, or throat) or difficulty breathing, seek medical attention immediately.

Q: Can I take Метеоспазмил with other medications?

A: It is important to consult a healthcare professional or pharmacist before taking Метеоспазмил with any other medications, including prescription, over-the-counter, or herbal remedies. They can check for potential interactions to ensure the safety and effectiveness of your treatment.

Q: Is Метеоспазмил the same as Mebeverine or other antispasmodics?

A: No, Метеоспазмил is not the same as Mebeverine, although both are used as antispasmodics. Метеоспазмил is a fixed-dose combination of Alverine citrate (the antispasmodic) and Simethicone (for gas relief). Other antispasmodics like Mebeverine contain only a single active ingredient.

How to Store and Dispose of Meteospasmyl?

The storage requirements for Meteospasmyl soft capsules are defined by official regulatory documentation, which specifies conditions based on the packaging type to ensure product stability and the labeled 3-year shelf life.

Storage Conditions

Packaging Type	Required Temperature Condition
PVC/Aluminium Blister Packs	Store below 30 C
PVC/PE/PVDC-Aluminium Blister Packs	No special temperature conditions required

All medicinal products must be kept out of the sight and reach of children.

Disposal

Official instructions mandate that unused or expired Meteospasmyl must be disposed of according to local requirements. The product must not be disposed of via wastewater or regular household waste to comply with environmental protection protocols.